December 9th 2024
HepB-CpG achieved superior seroprotection response versus conventional HepB-alum in patients with HIV and nonresponse to prior hepatitis B vaccination.
FDA Committee Votes Against Risk-Benefit Profile of OCA 25 mg for NASH
May 20th 2023The June 22, 2023 PDUFA date for obeticholic acid 25 mg oral tablets for the treatment of precirrhotic liver fibrosis appears to be in jeopardy after a May 23, 2023 meeting of the FDA's Gastrointestinal Drugs Advisory Committee.
Metabolic Syndrome Could Worsen Damaging Effects of Alcohol Use on Liver
May 12th 2023Despite stable rates of heavy alcohol use, deaths from alcohol-associated liver damage have risen in the US. A new study suggests an increase in the damaging effects of alcohol use in people with metabolic syndrome could be driving this apparent increase.
Increases in Acetic and Propionic Acids Found in NAFLD Patients With SARS-CoV-2
The investigators also found impaired biosynthesis of short-chain fatty acids in the coprofiltrate after analyzing the intestinal microbiome of patients with NAFLD who had SARS-CoV-2, manifested by an increase in the median acetic and propionic acids, as well as a decrease in the median butyric acid.
More Socially Vulnerable Areas in the US Associated With Higher Liver-Related Mortality
Counties with high liver transplantation registration rates and high liver-related mortality rates had comparable data on social vulnerability index, while travel distance was relatively shorter.